724 reports of this reaction
3.2% of all ALTEPLASE reports
#6 most reported adverse reaction
HAEMORRHAGE INTRACRANIAL is the #6 most commonly reported adverse reaction for ALTEPLASE, manufactured by Genentech, Inc.. There are 724 FDA adverse event reports linking ALTEPLASE to HAEMORRHAGE INTRACRANIAL. This represents approximately 3.2% of all 22,483 adverse event reports for this drug.
Patients taking ALTEPLASE who experience haemorrhage intracranial should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE INTRACRANIAL is moderately reported among ALTEPLASE users, representing a notable but not dominant share of adverse events.
In addition to haemorrhage intracranial, the following adverse reactions have been reported for ALTEPLASE:
The following drugs have also been linked to haemorrhage intracranial in FDA adverse event reports:
HAEMORRHAGE INTRACRANIAL has been reported as an adverse event in 724 FDA reports for ALTEPLASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE INTRACRANIAL accounts for approximately 3.2% of all adverse event reports for ALTEPLASE, making it a notable side effect.
If you experience haemorrhage intracranial while taking ALTEPLASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.